U.S. Food, 2011-07-26: The 26 July 2011 FDA Drug Safety Communication announcing that methylene blue is a monoamine oxidase A inhibitor and that giving it to patients on serotonergic psychiatric medications can precipitate serotonin syndrome. It says methylene blue should generally not be given to such patients except in emergencies (methemoglobinemia, ifosfamide encephalopathy, cyanide poisoning).
The U.S. Food and Drug Administration (FDA) has received reports of serious central nervous system (CNS) reactions when the drug methylene blue is given to patients taking psychiatric medications that work through the serotonin system of the brain (serotonergic psychiatric medications).
U.S. Food, 2011-07-26: The 26 July 2011 FDA Drug Safety Communication announcing that methylene blue is a monoamine oxidase A inhibitor and that giving it to patients on serotonergic psychiatric medications can precipitate serotonin syndrome. It says methylene blue should generally not be given to such patients except in emergencies (methemoglobinemia, ifosfamide encephalopathy, cyanide poisoning). Study type: regulatory record.
